Dedicated Training Course “Oncology Drug Development in Practice” (ODDP) (ODDP)

Venue: Dorint Hotel Amsterdam-Airport

Location: Amsterdam, Namibia

Event Date/Time: Nov 27, 2012 End Date/Time: Oct 30, 2012
Report as Spam


The development of new therapeutic agents for cancer is an important objective of many companies and cancer research institutes. This 4-day educational activity, offered by Congress by design (formerly MCCM Meeting Management) and INC Research, Inc., teaches knowledge and skills needed by professionals in oncology drug development in daily practice. It is the continuation of a highly successful program offered annually since 2004.

Educational aims
Oncology drug development is distinctly different from drug development in other therapeutic areas. The specific features of the preclinical and clinical development of new therapeutic agents for the treatment of cancer, in particular in Europe, will be addressed during this course. The course will cover the complete development process, starting with a preclinically identified development candidate through post-registration clinical studies. It will also address general aspects of (medical) oncology as well as strategic and regulatory issues in the development of cancer therapeutics.

Main themes

• Carcinogenesis & tumor biology (A)
• Diagnostic techniques in cancer (A)
• Principles of medical oncology (A)
• Current treatment strategies in selected solid tumors and haematological malignancies (A)
• Medical image management and tumor response evaluation (A)
• Preclinical drug development (B)
• Early phase clinical studies (B)
• Full clinical development (B)
• Post-registration studies (B)
• Molecular diagnostics in patient management and drug development (B)
• Clinical trial design in oncology (B)
• Regulatory environment for anticancer drug development (B)

Educational themes will be elaborated by experts from leading academic research institutes and oncology-orientated drug companies, all having ample expertise and hands-on experience in cancer research, clinical oncology, or anticancer drug development. This ensures that the education provided will be highly contemporary, fitting current drug development practice in oncology.

Who should participate?
The course is intended for everyone wishing to acquire or improve professional skills in the development of new cancer therapeutics. The education offered will be particularly useful for professionals in industry and the CRO environment, but others may benefit from participating as well. An understanding of the basic principles of biology and medicine at the graduate level is required for successful participation.


Stationsplein ZW 951

Additional Information

Tuition Full participant (themes A and B): EUR 3,350 Themes A only: EUR 1,950 Themes B only: EUR 2,150